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Abstract
Objective This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and safety properties of the test (CJ-
40001) and reference  (NESP®) versions of darbepoetin alfa following a single subcutaneous (SC) or intravenous (IV) 
administration in healthy male subjects.
Methods A single-blind, randomized, single-dose, two-period, two-intervention crossover study was conducted, with two 
separate parts consisting of SC or IV administration. In each period, either a test or reference product was administered via 
the SC or IV route. Serial blood samples for PK analysis and the reticulocyte, hematocrit, hemoglobin, and red blood cell 
counts for PD analysis were collected for up to 360 or 264 h after SC or IV administration, respectively. The PK and PD 
parameters were calculated using non-compartmental methods. The 90% confidence intervals of the geometric mean ratios 
for the PK and PD parameters between the two interventions were estimated. Safety and anti-drug antibody profile assess-
ments were performed.
Results The mean darbepoetin alfa concentration–time profiles were comparable between the two products for SC and IV 
administration. Additionally, the PD and safety profiles were similar between the two products. Anti-drug antibody reac-
tivity was negative for all samples from both intervention groups for SC and IV administration. The time-matched serum 
darbepoetin alfa concentration and the PD markers presented a counter-clockwise hysteresis, which suggests a time delay 
between the exposure and response.
Conclusion The test and reference darbepoetin alfa formulations had similar PK, PD, and safety profiles. Thus, it is expected 
that the two formulations are able to be used interchangeably in clinical settings.
ClinicalTrials.gov Identifier: NCT03542916.
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Key Points 
This is the first report on the pharmacokinetic and phar-
macodynamic characteristics of CJ-40001, a biosimilar 
darbepoetin alfa.
Based on the comparable pharmacokinetics, pharmaco-
dynamics, and safety profiles of the test and reference 
darbepoetin alfa, it is expected that they can be used 
interchangeably.
1 Introduction
Anemia is a common finding in patients with chronic kidney 
disease (CKD) and in those with cancer who are receiving 
multiple-cycle chemotherapy [1–6]. The anemia associated 
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with CKD has a multifactorial pathology that includes rela-
tive erythropoietin (EPO) deficiency, uremic-induced inhibi-
tors of erythropoiesis, shortened erythrocyte survival, and 
disordered iron homeostasis [2]. The etiology of chemother-
apy-related anemia is also multifactorial, resulting from the 
myelosuppressive effects of chemotherapy and the direct 
effects on the renal tubules, decreasing the production of 
the EPO [7].
EPO is a glycoprotein hormone that regulates erythro-
poiesis and plays a crucial role in erythrocyte production 
and maturation [1, 8, 9]. EPO is mainly produced in the 
peritubular cells of the kidneys in adults and in hepatocytes 
in the fetus [1]. Hypoxia leads to an increase in EPO pro-
duction, and EPO controls red blood cell (RBC) production 
[1, 10]. The management of CKD or chemotherapy-related 
anemia was revolutionized by the introduction of recombi-
nant human EPO (rHuEPO), one of the key medications for 
these types of anemias [1, 2, 11–13]. However, according to 
the recommended use of rHuEPO, patients should receive 
the medicine two to three times a week via an invasive route 
[subcutaneous (SC) or intravenous (IV) injection] [14]. Dif-
ficulties relating to this type and frequency of administration 
led to the development of molecules with improved in vivo 
bioactivity that can reduce the frequency of administration. 
This research resulted in the discovery and development of 
the second-generation rHuEPO, darbepoetin alfa  (NESP®, 
Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), which can 
be administered less frequently than the first-generation 
rHuEPO [14, 15], and the US Food and Drug Administra-
tion (FDA) approved darbepoetin alfa for the treatment of 
CKD-associated anemia in 2001 [16].
The pharmacokinetic (PK) and pharmacodynamic (PD) 
relationship in reference darbepoetin alfa following inten-
sive sampling has rarely been reported [17]. In addition, it 
has also not been reported whether such studies have been 
conducted under conditions where potential confounding 
factors were controlled. We therefore conducted a study of 
the PK–PD relationship and safety profile of test darbepoetin 
alfa (CJ-40001, CJ HealthCare Corp., Seoul, Korea) com-
pared with that of the reference darbepoetin alfa  (NESP®) 
given via two administration routes, SC and IV, in healthy 
volunteers.
2  Methods
2.1  Study Design
This study was conducted in accordance with the ethical 
principles of the 1964 Helsinki Declaration and the Korean 
Good Clinical Practices [18]. This study was a single-blind, 
randomized, single-dose, two-period, two-intervention 
crossover study, with two separate parts (Fig. 1). Before 
enrollment and any study-related procedures were per-
formed, informed consent was obtained from all individual 
subjects included in the study. In each part, subjects who 
were eligible based on the inclusion/exclusion criteria were 
randomized to one of two sequence groups where they would 
each be administered a single dose of reference and test drug 
according to the sequence allocated to them.
Healthy male adults aged 19–55 years with a body mass 
index of 19–28 kg/m2 were eligible. Subjects who showed 
at least one of the following clinical laboratory results were 
excluded: blood hemoglobin (Hb) value < 13 or > 17 g/dL; 
blood reticulocyte (Ret) value more than the upper reference 
limit (2%); and/or blood vitamin  B12 (211 pg/mL), ferri-
tin (22 ng/mL), or transferrin (200 mg/dL) value less than 
the lower reference limit. Major exclusion criteria were the 
Assessed for eligibility (n=118)
Ineligible (n=56)
Withdrawal by subject (n=5)
Lost to follow-up (n=1)
Part 1, Subcutaneous administraon Part 2, Intravenous administraon
Randomizaon (n=28) Randomizaon (n=28)
Reference → Test Test → Reference Reference → Test Test → Reference
Allocated to intervenon (n=14) Allocated to intervenon (n=14) Allocated to intervenon (n=14) Allocated to intervenon (n=14)
- Received (n=13) - Received (n=14) - Received (n=13) - Received (n=14)
- Not received - Not received 
(Withdrawal by subject, n=1) (Withdrawal by subject, n=1)
Disconnued (n=0) Disconnued (n=1) Disconnued (n=2 ) Disconnued (n=1)
- Lost to follow-up  (n=1) - Withdrawal by subject (n=2) - Physician decision (n=1)
Analysed (n=13) Analysed (n=13) Analysed (n=11) Analysed (n=13)
Fig. 1  Study design and subject disposition
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following: history of drug abuse; history of major illness; 
positive status for HIV, syphilis, or hepatitis B or C; and 
clinically abnormal laboratory and 12-lead electrocardiog-
raphy (ECG) safety parameters.
The intra-subject variability of the maximum serum con-
centration (Cmax) and the area under the concentration–time 
curve (AUC) to the last measurable concentration (AUC last) 
was assumed to be 20% and 15%, respectively, based on 
the previous report of darbepoetin alfa [19]. With a sample 
size of 20, a difference of 20% in the log-transformed PK 
parameters could be detected with a 90% test power at a sig-
nificance level of 0.05. The total number of subjects for each 
part was 28 (14 subjects per sequence group), which could 
accommodate an approximate dropout rate of 25% [20].
The enrolled subjects were randomly allocated to one of 
the two sequences and received a single SC or IV injection 
of 60 µg of either the test drug (CJ-40001; CJ HealthCare 
Corp.) or the reference drug  (NESP® Prefilled Syringe 60; 
Kyowa Hakko Kirin Co., Ltd.) after 10 h of fasting (Fig. 1). 
Depending on the part, the study drug was administered via 
the SC or IV route on the upper arm. A washout period of 
35–49 days (representing at least a five-fold terminal elimi-
nation half-life (t½) of darbepoetin alfa) was placed between 
the two periods to allow sufficient elimination of the drug 
administered in the previous period [19]. Blood samples for 
the PK assessment were obtained at predose and at 2, 4, 8, 
12, 24, 36, 48, 72, 96, 120, 168, 216, 264, and 360 h post-
dose in each period in part 1 and at predose and 0.25, 0.5, 
1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 168, 216, and 264 h 
postdose in each period in part 2. For the PD assessment, 
the Ret count (%), hematocrit (Hct; %), Hb (g/L), and RBC 
count  (106/mm3) were measured at predose and 24, 36, 48, 
72, 96, 120, 168, 216, 264, and 360 h postdose in part 1 
and at predose and 24, 36, 48, 72, 96, 120, 168, 216, and 
264 h postdose in part 2. We assessed the anti-drug antibody 
(ADA) formation after darbepoetin alfa administration only 
in period 1. By doing this, we could rule out the carry-over 
effect in immunogenicity assessment.
2.2  Bioanalytical Methods
Serum darbepoetin alfa concentrations were quantified by 
a validated enzyme-linked immunosorbent assay (ELISA) 
method with a  Quantikine®  IVD® ELISA, a human EPO 
immunoassay kit (R&D Systems Inc., Minneapolis, MN, 
US; Lot number: 323465) [21, 22]. The quantification of 
EPO was made without distinction between endogenous 
EPO and darbepoetin alfa. The calibration standard sam-
ples of seven different concentrations (except the blank sam-
ple) constructed the calibration curve. Calibration curves of 
the test and reference showed linearity between 0.156 and 
5 μg/L, and the lower limit of quantification for darbepo-
etin alfa was 0.156 μg/L. Samples expected to exceed the 
upper limit of the linear range were diluted before analysis 
with specimen diluent of the enzyme immunoassay kit. The 
intra- and inter-assay precision was 1.8% and 9.9%, respec-
tively. The back-calculated concentration ranged from 84.0 
to 105.8% at the lower limit of quantification (0.156 ng/mL), 
98.8 to 101.6% at the upper limit of quantification (5 ng/
mL), and 94.9 to 105.9% at the other concentrations.
To measure the ADA levels, the bridging ELISA method 
was used. The assay system utilized a biotin-labeled drug 
(test), a fluorescein-labeled drug, and an anti-fluores-
cein antibody. First, the positive control in human serum 
(100 μL), the biotin-labeled drug (100 μL), and the fluo-
rescein-labeled drug (100 μL) were incubated simultane-
ously for 1 h in a polypropylene 96-well plate at 37 °C with 
shaking and then incubated overnight at 4 °C. This solu-
tion was then transferred to a streptavidin-coated microtiter 
plate, blocked with phosphate-buffered saline with  Tween® 
20 tablets, pH 7.4 (Takara Bio, Inc., Shiga, Japan) with 
0.5% bovine serum albumin, and incubated for 1 h at room 
temperature. After removing the solution and washing, anti-
fluorescein antibody and 3,3ʹ,5,5ʹ-tetramethylbenzidine were 
reacted on a plate.
The analyses of the hematologic parameters for PD 
assessment were conducted in the Department of Laboratory 
Medicine, Samsung Medical Center (SMC; Seoul, Republic 
of Korea). The Ret count, Hct, Hb, and RBC count were 
determined by flow cytometry using a Sysmex XE-2100 
Hematology Autoanalyzer (Sysmex Corporation, Kobe, 
Japan).
2.3  Pharmacokinetic and Pharmacodynamic 
Analyses
The non-compartmental PK analysis of darbepoetin alfa 
was performed with  Phoenix®  WinNonlin® (version 
7.1.0; Certara USA, Inc., Princeton, NJ, USA). The Cmax 
and the time to Cmax (tmax) were taken directly from the 
observed values. The AUC last and the AUC from time 
zero to infinity (AUC ∞) were calculated by the linear-up/
log-down method. The elimination rate constant (λz) was 
estimated by a linear regression of the log-linear decline 
of the concentration–time curve. The t½ was calculated as 
ln2/λz. The clearance (CL) and apparent clearance  (CLapp) 
were calculated by dividing the administered dosage by 
the AUC ∞. The volume of distribution (Vd) and apparent 
volume of distribution (Vdapp) were calculated by divid-
ing the CL and  CLapp by λz. Since the PK characteristics 
of darbepoetin alfa after SC or IV administration were 
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assessed in different subjects in separate parts of the 
study, we did not assess the bioavailability of darbepo-
etin alfa.
The time courses of the Ret count, Hct, Hb, and RBC 
count were investigated and compared between the test 
and reference drugs as PD markers. The maximum effect 
(Emax) and the time to Emax (tEmax) were taken directly 
from the observed values. The AUC from time zero to the 
last point of quantifiable effect  (AUEClast) was calculated 
using the linear trapezoidal method.
2.4  Safety Analysis
All adverse events (AEs) were recorded on investiga-
tors’ questionnaires or subjects’ spontaneous reports. 
Physical examinations, vital-sign measurements, 
12-lead ECGs, and laboratory testing (hematology, 
clinical chemistry, coagulation, and urinalysis) were 
performed at predefined, regular intervals through-
out the studies and all clinically significant abnormal 
changes in the test results were reported as AEs. All 
AEs were assessed by the investigators with respect to 
severity, course, outcome, seriousness, and relation-
ship to the study drug and were recorded regardless 
of the suspected relationship to the study drug. The 
clinical laboratory tests were performed by the Depart-
ment of Laboratory Medicine at SMC. The laboratory 
is accredited by the College of American Pathologists, 
and quality control was ensured according to the inter-
nal standard operating procedures of SMC.
2.5  Statistical Analysis
Statistical analysis was carried out with  SAS® Enterprise 
 Guide® (version 7.1; SAS Institute Inc., Cary, NC, USA). 
The descriptive statistics of PK and PD variables for each 
analyte were summarized by intervention. The PK com-
parison was performed using the Cmax and AUC last. For the 
log-transformed PK parameters, linear mixed-effect analysis 
of variance was performed with fixed effects for the for-
mulation, period, and sequence and a random effect for the 
subject nested for the sequence. The geometric mean ratio 
of the test to the comparator and the 90% confidence interval 
(CI) for each PK parameter was calculated. The test drug 
was considered to demonstrate a PK equivalence with the 
reference drug if the 90% CI for each PK parameter was 
within the range of 0.80–1.25. The PD parameters were 
log-transformed and then the significance of the difference 
between the two interventions was tested using the analysis 
of covariance (linear mixed model) including predose con-
centration as a covariate. For tEmax, the significance of the 
difference between the two interventions was tested using 
the Wilcoxon signed rank test without log-transformation.
3  Results
3.1  Demographics
A total of 28 subjects were enrolled in both parts 1 and 2. 
A summary of the demographic data according to the study 
part is shown in Table 1. There were five and nine subjects 
who were smokers in parts 1 and 2, respectively, and the 
Table 1  Demographic characteristics
Values are presented as the mean ± standard deviation
BMI body mass index
a Student’s t test
Variables Sequence Total p  valuea
Reference → test Test → reference
Part 1: subcutaneous administration of darbepoetin alfa 60 µg
 Number of subjects 14 14 28
 Age (years) 32.64 ± 8.77 31.50 ± 7.29 32.07 ± 7.93 0.7107
 Height (cm) 173.29 ± 4.66 173.67 ± 4.33 173.48 ± 4.42 0.7940
 Weight (kg) 68.86 ± 6.36 68.24 ± 6.24 68.55 ± 6.19 0.8224
 BMI (kg/m2) 22.93 ± 1.88 22.62 ± 1.80 22.77 ± 1.81 0.6628
Part 2: intravenous administration of darbepoetin alfa 60 µg
 Number of subjects 14 14 28
 Age (years) 30.00 ± 7.50 29.07 ± 9.09 29.54 ± 8.19 0.7706
 Height (cm) 171.41 ± 7.41 173.93 ± 5.68 172.67 ± 6.60 0.2868
 Weight (kg) 67.09 ± 8.32 70.40 ± 7.76 68.75 ± 8.07 0.3216
 BMI (kg/m2) 22.81 ± 2.17 23.22 ± 1.65 23.02 ± 1.90 0.5783
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mean (standard deviation) amounts of smoking were 7.0 
(2.8) and 6.6 (3.5) cigarettes/day in parts 1 and 2, respec-
tively. Demographic and other baseline characteristics were 
not significantly different between the two sequences in both 
parts. In part 1, there were two dropouts: one before and one 
after the investigational product administration. In part 2, 
there were four dropouts: one before and three after receiv-
ing the investigational product. Hence, 26 and 24 subjects 
completed the study in parts 1 and 2, respectively.
3.2  Pharmacokinetic Analysis
A summary of the PK parameters of darbepoetin alfa is 
presented in Table 2. The mean serum concentration–time 
profiles after SC or IV administration of the test or reference 
product are shown in Fig. 2.
3.2.1  Part 1: Subcutaneous Administration
The serum concentrations of darbepoetin alfa peaked at a 
median of approximately 24 h for the test and reference 
product after SC administration (Fig. 2a). The serum level 
of darbepoetin alfa decreased with similar elimination 
curves between interventions. The mean AUC last and Cmax 
values of the test product were 249.62 h·μg/L and 2.44 μg/L, 
respectively; the corresponding values of the reference prod-
uct were 262.68 h·μg/L and 2.64 μg/L, respectively. The 
geometric mean ratios of the AUC last and Cmax between 
the test and reference product after SC administration 
were 0.9533 (90% CI 0.9110–0.9976) and 0.9326 (90% CI 
0.8689–1.0009), respectively (Table 3). The differences 
between interventions of exposure after SC administration 
were not significant.
3.2.2  Part 2: Intravenous Administration
The serum level of darbepoetin alfa decreased with similar 
elimination curves after IV administration between inter-
ventions (Fig. 2b). The arithmetic means of the darbepoetin 
alfa AUC last value for the reference and test were 479.78 
and 466.86 h·μg/L, respectively, and the arithmetic means 
of the darbepoetin alfa Cmax value for the reference and test 
were 18.64 and 17.78 μg/L, respectively. The geometric 
mean ratios of the AUC last and Cmax between the test and 
reference product after IV administration were 0.9798 (90% 
CI 0.9205–1.0429) and 0.9701 (90% CI 0.8883–1.0594), 
respectively (Table 3). There was no significant difference 
in exposure between the two interventions.
3.3  Pharmacodynamic Analysis
The mean Ret counts increased up to 168 and 120 h after 
the SC and IV drug administration and then decreased until 
the last observed time (Fig. 3). In both parts, the  AUEClast 
and Emax of the PD analytes were comparable between the 
test and the reference product (Table 4). Moreover, the 
time courses for the changes in PD analytes were similar 
between the test and reference drug (Table 4; Fig. 3). The 
time-matched PK and PD markers presented a counter-
clockwise hysteresis, which suggests a time delay between 
the change in serum concentration of darbepoetin alfa and 
the PD response (Fig. 4). From the timepoints at which both 
PK and PD were measured, the highest level of darbepoetin 
alfa concentration and Ret count were observed at 24 and 
168 h after administration of darbepoetin alfa, respectively, 
in both part 1 and part 2.
3.4  Safety
A total of 54 subjects (part 1: 27, part 2: 27) received at 
least one dose of the test or reference drug. The treatment-
emergent AEs that occurred in two or more subjects are 
shown in Table 5. No serious AE- and AE-related dropouts 
occurred during the study. All AEs were mild to moder-
ate in severity and were recovered without sequelae. Fre-
quencies of treatment-emergent AEs were similar between 
Table 2  Summary of pharmacokinetic variables for darbepoetin alfa
Data are presented as the mean ± standard deviation unless stated oth-
erwise
AUC ∞ area under the concentration–time curve from time zero to 
infinity, AUC last area under the concentration–time curve to the last 
measurable concentration, CL clearance, CLapp apparent clearance, 
Cmax maximum serum concentration, t½ terminal elimination half-life, 
tmax time to maximum observed serum concentration, Vd volume of 
distribution, Vdapp apparent volume of distribution
a Data presented as median (minimum–maximum)
Variables Test Reference
Part 1: subcutaneous administration of darbepoetin alfa 60 µg
 Number of subjects 27 26
 tmax (h)a 24.08 (12–48) 24.03 (8–48)
 Cmax (μg/L) 2.44 ± 0.74 2.64 ± 0.81
 AUC last (h·μg/L) 249.62 ± 56.30 262.68 ± 57.42
 AUC ∞ (h·μg/L) 294.93 ± 62.81 310.37 ± 79.18
 t½ (h) 134.17 ± 45.52 135.57 ± 62.53
 CLapp (L/h) 0.21 ± 0.05 0.21 ± 0.05
 Vdapp (h) 40.11 ± 13.33 37.86 ± 12.08
Part 2: intravenous administration of darbepoetin alfa 60 µg
 Number of subjects 25 26
 Cmax (μg/L) 17.78 ± 2.34 18.64 ± 3.80
 AUC last (h·μg/L) 466.86 ± 83.46 479.78 ± 86.92
 AUC ∞ (h·μg/L) 505.14 ± 99.72 516.30 ± 89.75
 t½ (h) 121.43 ± 59.75 119.05 ± 53.23
 CL (L/h) 0.12 ± 0.02 0.12 ± 0.03
 Vd (h) 20.45 ± 7.69 20.48 ± 9.77
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the test and reference drug in parts 1 (p = 0.4152) and 2 
(p = 0.2528). Clinical laboratory evaluation of hematology, 
blood chemistry, and urinalysis throughout the study showed 
no unexpected changes that could be attributed to the test 
and reference drugs. There was no clinically significant 
finding in the vital signs, ECGs, and physical examination 
results in all interventions. The ADA reactivity was negative 
for all samples from both intervention groups regardless of 
Fig. 2  Mean serum concentra-
tion–time profiles of darbepoe-
tin alfa after a subcutaneous and 
b intravenous administration of 
the test or reference formula-
tion. Note: bars represent 
standard deviations
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Table 3  Pharmacokinetic comparison of darbepoetin alfa between interventions
AUC last area under the concentration–time curve to the last measurable concentration, Cmax maximum serum concentration, CV coefficient of 
variation
a Transformed back to the original scale after statistical analysis using log-transformed data
Variables Geometric least square mean (CV) Geometric mean ratio 
(90% confidence 
interval)aTest Reference
Part 1: subcutaneous administration of darbepoetin alfa 60 µg
 Number of subjects 27 26
 AUC last (h·μg/L) 241.13 (22.56) 252.95 (21.86) 0.9533 (0.9110–0.9976)
 Cmax (μg/L) 2.35 (30.17) 2.52 (30.69) 0.9326 (0.8698–1.0009)
Part 2: intravenous administration of darbepoetin alfa 60 µg
 Number of subjects 25 26
 AUC last (h·μg/L) 457.93 (17.88) 467.36 (18.12) 0.9798 (0.9205–1.0429)
 Cmax (μg/L) 17.97 (13.16) 18.52 (20.38) 0.9701 (0.8883–1.0594)
Fig. 3  Mean pharmacodynamic variable–time profiles of darbepoetin alfa after a subcutaneous and b intravenous administration of the test or 
reference formulation. Note: bars represent standard deviations
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administration route. Administration of the test drug given 
as a single SC or IV injection was safe and well-tolerated in 
healthy male subjects and the frequency of AEs was similar 
to that in the reference drug.
4  Discussion
This study was designed to evaluate the PK, PD, and safety 
profiles of test and reference darbepoetin alfa given as a sin-
gle SC or IV injection in healthy male subjects. The test 
darbepoetin alfa exhibited comparable safety, PK, and PD 
profiles to the reference drug in both administration routes.
For the PKs, the CIs of the geometric mean ratios (test 
to reference) for Cmax and AUC last fell within the accept-
ance criteria of 0.80–1.25 with both SC and IV adminis-
tration. The inter-subject variabilities of PK variables for 
the test drug were similar to those for the reference drug in 
both administration routes. The t½ of darbepoetin alfa was 
longer following SC injection than following IV injection 
for the test drug, which is consistent with the previously 
reported results for the reference product [19, 23]. The t½ 
of darbepoetin alfa after SC administration reflects flip-flop 
kinetics [23]. In this study, the t½ of the reference darbepo-
etin alfa following IV injection was 119.05 h, which is four 
times more than that of a previous report (25.3 h) [19]. This 
study employed more protracted sampling periods (up to 
360 h) than the previous study (96 h) and the t½ calculated 
from data with the same last timepoint (96 h) as the previ-
ous study is 20.4 h. The t½ of darbepoetin alfa in healthy 
subjects after SC administration is not reported. For refer-
ence, the t½ was reported to be 48.8 h in dialysis patients 
with blood sampling up to 168 h after SC administration of 
darbepoetin alfa [24]. Meanwhile, since the quantification 
of EPO was made without distinction between endogenous 
EPO and darbepoetin alfa, correction to a baseline value was 
Fig. 3  (continued)
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plausible for PK analysis. However, in this study, baseline 
correction was not carried out because most baseline values 
were below the lower limit of quantification.
It is recommended that darbepoetin alfa be administered 
once a week or every 2 weeks for patients with CKD on 
dialysis and with 4-week intervals for patients with CKD 
not on dialysis [25, 26]. The Hct, Hb, and RBC counts that 
reflect erythropoiesis increased up to 360 h, while the Ret 
counts recovered to baseline levels after an initial incremen-
tal increase following SC injection of darbepoetin alfa. Fol-
lowing IV injection, Hct, Hb, and RBC counts increased 
for 216  h and then decreased thereafter, while the Ret 
Table 4  Summary of pharmacodynamic variables for darbepoetin alfa between interventions
Data are presented as the geometric least square mean (coefficient of variation) unless specified otherwise
AUEClast area under the effect–time curve from time zero to the last point of quantifiable effect, Emax maximum effect, tEmax time to maximum 
effect
a Linear mixed model with intervention, period, sequence, group, and sequence-nested subject effect and predose value as a covariate for 
 AUEClast and Emax, while the Wilcoxon signed rank test was the source for tEmax
b Data presented as median (minimum–maximum)
Variables Test Reference p  valuea
Part 1, subcutaneous administration of darbepoetin alfa 60 µg
 Number of subjects 27 26
 Reticulocyte count
  AUEClast (h·%) 623.5 (23.7) 628.9 (24.3) 0.5159
  Emax (%) 2.45 (22.6) 2.47 (26.2) 0.6802
  tEmax (h)b 168.0 (95.9–168.7) 168.0 (119.7–168.9) 0.3426
 Hematocrit
  AUEClast (h·%) 15,866 (5.07) 15,833 (4.80) 0.6694
  Emax (%) 46.1 (5.24) 45.8 (4.39) 0.4557
  tEmax (h)b 168.0 (95.9–168.7) 264.1 (72.0–361.2) 0.9696
 Hemoglobin
  AUEClast (h·g/dL) 5371 (5.37) 5353 (5.49) 0.5707
  Emax (g/dL) 15.6 (5.58) 15.5 (5.04) 0.9713
  tEmax (h)b 263.9 (0.0–360.9) 264.1 (24.0–361.2) 0.6238
 Red blood cell count
  AUEClast (h·106/μL) 1776 (5.34) 1767 (5.20) 0.9433
  Emax  (106/μL) 5.15 (5.58) 5.11 (4.83) 0.4708
  tEmax (h)b 263.5 (24.0–360.9) 264.6 (72.0–361.2) 0.7127
Part 2: intravenous administration of darbepoetin alfa 60 µg
 Number of subjects 25 26
 Reticulocyte count
  AUEClast (h·%) 510.2 (19.5) 500.5 (20.0) 0.0735
  Emax (%) 2.65 (18.6) 2.60 (21.3) 0.4007
  tEmax (h)b 120.1 (72.0–168.8) 120.1 (96.2–168.6) 0.7174
 Hematocrit
  AUEClast (h·%) 11,735 (5.19) 11,705 (6.39) 0.6236
  Emax (%) 46.3 (5.47) 46.2 (6.36) 0.7122
  tEmax (h)b 215.9 (48.0–264.3) 215.6 (36.0–264.5) 0.6151
 Hemoglobin
  AUEClast (h·g/dL) 3995 (6.11) 3970 (6.99) 0.3561
  Emax (g/dL) 15.7 (6.53) 15.7 (7.06) 0.6233
  tEmax (h)b 168.1 (48.1–264.3) 120.1 (0.0–264.5) 0.7063
 Red blood cell count
  AUEClast (h·106/μL) 1304 (5.31) 1302 (6.50) 0.5796
  Emax  (106/μL) 5.13 (5.50) 5.12 (6.54) 0.2600
  tEmax (h)b 168.8 (48.1–264.3) 191.9 (24.0–264.5) 0.6418
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count–time profile was similar to that of the SC route. This 
may result from slow absorption along with the long dura-
tion of SC administration, which leads to sustained drug 
exposure and persistence of the effect. However, IV admin-
istration of darbepoetin alfa also showed an erythropoietic 
effect over sufficient time in this study. By examining the 
response after administration, in this study we again con-
firmed the appropriateness of the darbepoetin alfa regimens, 
including the IV route recommendation, for patients on 
hemodialysis [25].
Intensive PK–PD studies of darbepoetin alfa in healthy 
subjects have not been reported. However, we verified the 
relationship and time-dependent changes in the PK–PD 
relationship of darbepoetin alfa, revealing it to be a counter-
clockwise hysteresis loop. This characteristic of rHuEPO 
had already been reported in previous studies [22, 27]. The 
counter-clockwise hysteresis implies that there is a delay in 
equilibrium between the serum drug concentration and the 
PD effect [28] related to the maturation of normoblasts in 
bone marrow (3–7 days) [29–31].
The PKs and PDs of darbepoetin alfa are well-established 
in patient populations and healthy subjects. Thus, regarding 
assessment of rHuEPO biosimilars, PK and PD results with 
sufficient evidence to support a conclusion of no clinically 
meaningful differences may make a comparative efficacy 
study unnecessary in cases where there is a meaningful cor-
relation between the PK and PD results and clinical effec-
tiveness [32]. Although there are some patients who are 
resistant to rHuEPO, the cause of this is well-known and it 
has been established that rHuEPO shows a dose-proportional 
erythropoietic effect in about 90% of anemia patients [33, 
34]. Because of this, in general, the PK and erythropoetic 
responses to rHuEPO in patients with CKD are not expected 
to differ from those in healthy subjects [35, 36]. For refer-
ence, the PK/PD assessments in healthy subjects were con-
sidered the most perceptive in identifying the PK and PD 
response characteristics for a proposed biosimilar of epoetin 
alfa [37]. Furthermore, there is a known correlation between 
the Hb response and the improvement in quality of life after 
administration of darbepoetin alfa [38]. This study provides 
good evidence to enable prediction of the efficacy and effec-
tiveness in patients receiving darbepoetin alfa with regards 
to Hb response and quality of life.
Administration of a single dose of test and reference 
darbepoetin alfa was safe and well-tolerated in healthy 
male subjects. Observed AEs were consistent with the AEs 
reported in the prescribing information of  NESP® and no 
unexpected AEs were found following the administration 
of the test.
5  Conclusion
The test darbepoetin alfa had similar PK and PD charac-
teristics as the reference drug and the safety and immuno-
genicity profile was similar between the two interventions. 
In terms of PDs, the serum concentration of darbepoetin 
alfa and erythropoietic response showed hysteretic relation-
ships that were comparable between the two interventions. 
The similarities of the PK and PD properties and the safety 
a
b
Fig. 4  Relationship between mean serum darbepoetin alfa concentra-
tion and reticulocyte count after a subcutaneous and b intravenous 
administration of the test or reference formulation. Note: the symbols 
represent the mean pharmacokinetic–pharmacodynamic relationship 
at predose and 24, 36, 48, 72, 96, 120, 168, 216, 264, and 360 h after 
subcutaneous administration, and at predose and 24, 36, 48, 72, 96, 
120, 168, 216, and 264 h after intravenous administration
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profiles of the test and reference drug imply that they can be 
used interchangeably.
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